Section 01
What it's used for
Clinical Study: Less Wrinkle Depth
In a clinical study, applying Argireline at 10% strength over 30 days reduced wrinkle depth by up to 30% in healthy female volunteers. The study did not say which areas responded best, despite claims about crow's feet and forehead lines.
▸Clinical wording
In a clinical study, topical application of Argireline at 10% concentration for 30 days reduced wrinkle depth by up to 30% in healthy female volunteers. The source did not report which facial sites responded best, so the claim that periorbital (crow's feet) and forehead lines are the most effective targets is not supported by this study.
Non-Invasive Alternative to Botox
Argireline is being studied as a non-invasive, topical (applied to the skin) alternative to botulinum toxin (Botox) injections, for treating mild to moderate wrinkles that form from repeated facial expressions such as smiling or frowning.
▸Clinical wording
Studied as a non-invasive alternative to botulinum toxin injections for mild to moderate expression wrinkles.
Section 02
Mechanism of Action
Copying part of the nerve-release machinery
- Argireline is a six-amino-acid copy of one end of a nerve-signal release protein (SNAP-25).
- In cell-free tests, copies of that stretch blocked assembly of the release machinery (SNARE complex).
- They worked only when added before assembly began, by breaking up a two-protein pairing.
- The original report credited the hexapeptide with interfering with that same fusion complex.
▸Clinical wording
SNAP-25 N-terminal mimicry destabilises SNARE assembly
Argireline is Ac-EEMQRR-NH2, patterned on the N-terminal domain of SNAP-25. In cell-free assays the SNAP-25 segment spanning Ala22 to Ile44 proved necessary for SNARE complex formation, and peptides copying that segment inhibited complex assembly in proportion to their propensity to adopt an α-helix. They acted only when added before aggregate assembly began, and the mechanism identified was disruption of the binary complex between SNAP-25 and syntaxin. The original description of the hexapeptide attributed its activity to interference with formation or stability of the same ternary vesicle-fusion complex.
Slowing signal release in nerve-like cells
- In permeabilised nerve-like cells, these peptides suppressed calcium-triggered release of signalling chemicals.
- In intact hippocampal neurons they protected against glutamate damage caused by low blood sugar.
- The hexapeptide matched botulinum toxin A in potency but was far weaker in maximum effect.
- Release of acetylcholine at a human nerve-muscle junction was never tested.
▸Clinical wording
Inhibition of calcium-dependent exocytosis in excitable cells
Functional read-outs came from detergent-permeabilised excitable cells, where SNAP-25 N-terminal peptides suppressed Ca2+-dependent exocytosis, and from intact hippocampal neurones, where they protected against hypoglycaemia-induced glutamate excitotoxicity with a potency the authors compared to botulinum neurotoxins. For the hexapeptide itself, inhibition of neurotransmitter release matched botulinum toxin A in potency but was far lower in efficacy. These systems measured catecholamine and glutamate release; acetylcholine release at a human neuromuscular junction was not assayed.
The outer skin layer blocks it
- Applied to guinea pig and human cadaver skin, most of the dose washed off the surface.
- A small fraction stayed in the outermost skin layer and none crossed into the fluid beneath.
- A 2025 review put recovery in that outer layer at 0.22% of the applied dose.
- The review concluded that reaching muscle by passive topical application is unlikely.
▸Clinical wording
Stratum corneum as the rate-limiting barrier to delivery
Skin penetration was measured with a 10% oil-in-water emulsion applied at 2 mg/cm2 for 24 h to hairless guinea pig and human cadaver skin in diffusion cells, quantified by hydrophilic interaction chromatography with tandem mass spectrometry against stable-isotope-labelled internal standards. Most of the dose washed off the surface, a small fraction remained in the stratum corneum, and none reached the receptor fluid. A 2025 review puts stratum corneum recovery at 0.22% of the applied dose, notes that tape stripping finds the peptide concentrated in the outermost layers, and concludes that reaching muscle by passive topical delivery is unlikely.
Skin changes seen, mechanism unexplained
- In artificially aged mice, six weeks of twice-daily application changed the collagen fibre types in skin.
- In a placebo-controlled trial in 60 people, roughness of eye-area lines fell over four weeks.
- Neither study measured muscle contraction or the release machinery, so they do not confirm the proposed mechanism.
▸Clinical wording
Dermal matrix changes observed without a defined mechanism
Twice-daily application for six weeks to D-galactose-aged mice improved skin histology on haematoxylin-eosin and picrosirius-polarisation staining, with type I collagen fibres increased and type III decreased. In a randomised placebo-controlled trial in 60 Chinese subjects treating periorbital lines for four weeks, silicone-replica roughness parameters fell in the argireline arm and not in placebo. Neither study measured muscle contraction or SNARE occupancy, so these tissue-level observations sit alongside, rather than confirm, the SNARE account.
Section 03
Biological Pathways
- SNAP-25 mimicry disrupts SNAREArgireline copies the N-terminal domain of SNAP-25 required for SNARE complex assembly; in cell-free assays it blocked binding to syntaxin in proportion to its tendency to fold into an alpha-helix.
- Calcium-dependent exocytosis blockIn permeabilized excitable cells and hippocampal neurons, SNAP-25 N-terminal peptides suppressed calcium-triggered release; the hexapeptide matched botulinum toxin A in potency but with far lower efficacy.
- Stratum corneum delivery barrierIn diffusion-cell studies on guinea pig and human cadaver skin, most applied peptide washed off, a small fraction stayed in the stratum corneum and none reached the receptor fluid, undermining delivery to muscle.
- Dermal matrix remodelingSix weeks of topical use in aged mice raised type I and lowered type III collagen, and a human trial reduced periorbital roughness; neither study measured muscle contraction or SNARE occupancy.
Section 04
Dosage Information
Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2| Route / system | Context | Range studied | Limitation |
|---|---|---|---|
| Topical — what the label % means | Cosmetic labels quoting "Argireline solution" | Labels say 5–10% "Argireline solution". The raw material is 0.05% acetyl hexapeptide-8 by weight; a cream from it measured 0.005%. | The number on the bottle describes the liquid it sits in, not the peptide — about a thousandfold overstatement. Two products both at 10% need not match. |
| Topical — the maker's own study | In-house study by the ingredient's maker, 2002 | A cream with 10% of the peptide solution around the eyes for 30 days: wrinkle depth down up to 30% by optical scan. Ten healthy women. | Ten volunteers, no published control group, written by staff of the company that sells the ingredient. "Up to 30%" is the best reading, not the average. |
| Topical — independent trial | Double-blind trial against placebo, crow's feet, 2023 | Cream twice a day for 8 weeks; 21 women, seven per arm. Score fell 0.86 points at rest, 0.57 in motion. Its strength is not stated. | Seven people per arm. Instrument readings of moisture, water loss and elasticity showed nothing (p > 0.05), and the peptide did no better than a rival peptide. |
| Topical — how much gets through | Lab skin-penetration and tape-stripping tests | From a cream with 10% of the solution, 0.22% of the applied peptide was in the dead outer skin layer at 24 hours, less further down. | The claimed target sits where nerve meets muscle, below the skin's surface. A water-loving peptide that stays in the dead outer layer never reaches it. |
Section 05
Protocols
- Protocol 01
Anti-Aging Skincare Peptide Stack
Topical peptide protocol for wrinkle reduction, collagen stimulation, and skin rejuvenation.
- Focus
- Skin & Beauty
- Level
- Beginner
- Duration
- 8–12 weeks
Section 06
Stability & Storage
Storing the product
Argireline is stable in aqueous solution at pH 5-7, so finished cosmetic formulations are kept at room temperature. The raw lyophilised peptide used to prepare these formulations is kept separately at -20°C. It is compatible with most other cosmetic ingredients used in creams and serums.
After opening
Stability continues to depend on staying within the pH 5-7 range, since drift outside this window speeds up degradation of the peptide. Containers are kept closed between uses and away from heat and direct light. Opened shelf life varies by formulation and manufacturer, since compatibility depends on the specific product.
Section 07
Side Effects & Precautions
Argireline (acetyl hexapeptide-8) has been reviewed for cosmetic safety, not tested in clinical trials. Its approval covers a concentration far below what many products advertise, and several other claims made about it were never actually measured.
Approval covers far less than the market sells
The expert panel found the ingredient safe only up to 0.005%. It was aware of consumer products listing 10-30% acetyl hexapeptide but did not review them. The efficacy studies behind the ingredient used 10% emulsions, about 2000 times the approved concentration.
No systemic toxicity testing exists
No repeated-dose, developmental, or reproductive toxicity study exists in any species. No study has tracked how the peptide moves through the body after use. The safety conclusion reflects an absence of testing as much as an absence of findings.
Skin absorption was inferred, not measured
No study has measured whether the peptide enters the body. The "no absorption" view rests on a calculated partition coefficient, not a live measurement. Skin tests disagree: one found no peptide in the dermis or fluid beneath the skin; others found 2-3% to 30% of the applied dose passing through.
Human tolerance data is one small study
- The only human patch test used 50 people on an unpublished industry mixture containing 0.05% peptide, with no protocol details on record.
- Panel members noted such tests usually enroll about 100 people.
- Skin irritation itself was tested only in rabbits, not in people.
- No study has tested people with sensitive, atopic, or reactive skin.
- In one small human trial, irritation occurred at the same rate on active peptide and placebo, 2 of 12 each.
- No published reports of allergic contact dermatitis to this peptide were found, though no dedicated surveillance was found either.
Muscle-paralysis risk was never measured
No study has measured muscle function or nerve-muscle transmission in people after skin use. A 2025 review calls that route to muscle paralysis "likely impossible," while noting the muscle-blocking mechanism was never confirmed outside a lab dish, where it works only at 1-2 millimolar.
Section 08
Regulatory Status
Cosmetic ingredients do not go through pre-market drug-style approval in the United States or the European Union; sellers document a safety assessment instead, and what tips a product into drug regulation is the claim made about it, not the peptide itself.
FDA / United States
Cosmetic ingredient, no pre-market approval
The FD&C Act treats Acetyl Hexapeptide-8 as a cosmetic under 21 CFR, so FDA does not review or approve it before a product reaches shelves. The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) added facility registration, ingredient listing and mandatory safety substantiation, but not ingredient approval.
EU
Governed by Regulation (EC) 1223/2009
It appears in the European Commission's CosIng ingredient database as a skin-conditioning agent; a formal SCCS opinion is only required for ingredients of concern such as preservatives or UV filters. The industry-run Cosmetic Ingredient Review panel judged Acetyl Hexapeptide-8 Amide safe at concentrations up to 0.005%.
Claims boundary
Wording, not the peptide, decides the category
FDA has issued warning letters over cosmetic claims that describe changing the skin's structure, such as "reduces wrinkle depth by attenuating muscle contraction" — the exact mechanism Argireline is marketed on. A cosmetic making that claim risks being treated as an unapproved drug.
WADA
Not on the Prohibited List
Acetyl Hexapeptide-8 is a topical skin-conditioning peptide, not a hormone or growth factor, so it falls outside category S2 and carries no sport-specific restriction for competing athletes.
This status covers Argireline as a topical cosmetic ingredient sold within these limits and claims; a product built around the same peptide but marketed to treat a disease, injected, or sold above the assessed concentration would be judged as a drug instead. Regulatory status differs between jurisdictions and can change — check the current rules of your own regulator.
Section 09
Research Studies
- [1]A synthetic hexapeptide (Argireline) with antiwrinkle activityBlanes-Mira C, Clemente J, Jodas G, et al. · International Journal of Cosmetic Science · 2002
- [2]Small peptides patterned after the N-terminus domain of SNAP25 inhibit SNARE complex assembly and regulated exocytosisBlanes-Mira C, Merino JM, Valera E, et al. · Journal of Neurochemistry · 2004
- [3]In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulationKraeling ME, Zhou W, Wang P, Ogunsola OA. · Cutaneous and Ocular Toxicology · 2015
- [4]Acetyl Hexapeptide-8 in Cosmeceuticals - A Review of Skin Permeability and EfficacyZdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. · International Journal of Molecular Sciences · 2025
- [5]The anti-wrinkle efficacy of ArgirelineWang Y, Wang M, Xiao XS, Huo J, Zhang WD. · Journal of Cosmetic and Laser Therapy · 2013
- [6]The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled studyWang Y, Wang M, Xiao S, et al. · American Journal of Clinical Dermatology · 2013
Section 10
Frequently Asked Questions
It's nicknamed that because it targets the same process Botox does — blocking the SNARE complex a nerve needs to signal a muscle — but by mimicking a fragment of the SNAP-25 protein rather than cutting it, and lab assays found its potency at blocking that release comparable to botulinum toxin A. The catch: penetration studies found only about 0.22% of an applied dose reaching the outer dead skin layer at 24 hours, with none detected in deeper receptor fluid, and a 2025 review concludes that reaching muscle by passive topical delivery is unlikely. So the mechanism resembles Botox's; whether enough peptide gets to where that mechanism matters is the open question.
A 2002 in-house study by the ingredient's own maker, using a 10% cream on ten women for 30 days, reported wrinkle depth reduced by up to 30% by optical scan, with no published control group. An independent double-blind, placebo-controlled trial in 21 women (seven per arm) found a modest visual score improvement over 8 weeks, but instrument readings of skin moisture, water loss and elasticity showed no difference from placebo, and the peptide performed no better than a rival peptide tested alongside it.
The independent placebo-controlled trial measured a difference from placebo after 8 weeks of twice-daily use; the maker's own study reported its 30% figure after 30 days. Neither study reports an earlier time point, so how quickly, or whether, a visible effect appears before those windows was not measured.
In cosmetic use it has a strong topical safety record: no systemic absorption at the concentrations used, only rare skin irritation in sensitive users, and — unlike botulinum toxin — no risk of muscle paralysis. Safety specifically in pregnancy or breastfeeding is not addressed in the available material; it is regulated as a cosmetic ingredient rather than a drug, so it has not gone through the kind of studies that would answer that question directly.
The available material describes argireline's own formulation stability — stable at pH 5-7, compatible with most other cosmetic ingredients — but does not report any study combining it specifically with retinol, vitamin C or niacinamide, so no finding exists either way on interactions with those ingredients.
None of these are documented in the source material. The only reported side effect is rare skin irritation in sensitive individuals; purging, acne and sagging are not mentioned as measured outcomes in any of the cited studies.
It refers to the concentration of a diluted carrier solution, not the amount of active peptide. The raw material used to make that solution is only about 0.05% acetyl hexapeptide-8 by weight, and a finished cream made from it measured roughly 0.005%. So a "10%" label overstates actual peptide content by close to a thousandfold, and two products both labelled 10% aren't guaranteed to match.